TAK

A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs.

Keros Therapeutics announced the first patient dosing in its phase II study evaluating rinvatercept for Duchenne muscular dystrophy (DMD). The study will assess safety, tolerability, and functional improvements, with initial data expected in H1 2027. The company is also advancing rinvatercept development for ALS treatment and has a licensing agreement with Takeda Pharmaceutical for its second candidate, elritercept, with potential milestone payments exceeding $1.1 billion.

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access.

North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.